Analysis of Liquidity Ratios
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Illumina Inc., liquidity ratios
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Current ratio | 3.60 | 6.69 | 2.49 | 3.99 | 3.29 | |
| Quick ratio | 3.18 | 6.00 | 2.23 | 3.43 | 2.75 | |
| Cash ratio | 2.79 | 5.13 | 1.95 | 2.88 | 2.21 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Illumina Inc. current ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Illumina Inc. quick ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Illumina Inc. cash ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |
Current Ratio
Illumina Inc., current ratio calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 4,483) | 4,451) | 4,490) | 2,980) | 2,318) | |
| Current liabilities | 1,244) | 665) | 1,804) | 746) | 705) | |
| Liquidity Ratio | ||||||
| Current ratio1 | 3.60 | 6.69 | 2.49 | 3.99 | 3.29 | |
| Benchmarks | ||||||
| Current Ratio, Competitors2 | ||||||
| AbbVie Inc. | 0.84 | 3.18 | — | — | — | |
| Amgen Inc. | 1.81 | 1.44 | — | — | — | |
| Bristol-Myers Squibb Co. | 1.58 | 1.60 | — | — | — | |
| Danaher Corp. | 1.86 | 5.19 | — | — | — | |
| Eli Lilly & Co. | 1.40 | 1.16 | — | — | — | |
| Gilead Sciences Inc. | 1.40 | 3.10 | — | — | — | |
| Johnson & Johnson | 1.21 | 1.26 | — | — | — | |
| Merck & Co. Inc. | 1.02 | 1.24 | — | — | — | |
| Pfizer Inc. | 1.35 | 0.88 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 3.63 | 3.67 | — | — | — | |
| Thermo Fisher Scientific Inc. | 2.13 | 1.92 | — | — | — | |
| Zoetis Inc. | 3.05 | 2.63 | — | — | — | |
| Current Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 1.37 | 1.66 | — | — | — | |
| Current Ratio, Industry | ||||||
| Health Care | 1.21 | 1.34 | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= 4,483 ÷ 1,244 = 3.60
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Illumina Inc. current ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |
Quick Ratio
Illumina Inc., quick ratio calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and cash equivalents | 1,810) | 2,042) | 1,144) | 1,225) | 735) | |
| Short-term investments | 1,662) | 1,372) | 2,368) | 920) | 824) | |
| Accounts receivable, net | 487) | 573) | 514) | 411) | 381) | |
| Total quick assets | 3,959) | 3,987) | 4,026) | 2,556) | 1,940) | |
| Current liabilities | 1,244) | 665) | 1,804) | 746) | 705) | |
| Liquidity Ratio | ||||||
| Quick ratio1 | 3.18 | 6.00 | 2.23 | 3.43 | 2.75 | |
| Benchmarks | ||||||
| Quick Ratio, Competitors2 | ||||||
| AbbVie Inc. | 0.60 | 2.91 | — | — | — | |
| Amgen Inc. | 1.30 | 1.01 | — | — | — | |
| Bristol-Myers Squibb Co. | 1.28 | 1.26 | — | — | — | |
| Danaher Corp. | 1.36 | 4.68 | — | — | — | |
| Eli Lilly & Co. | 0.85 | 0.68 | — | — | — | |
| Gilead Sciences Inc. | 1.08 | 2.86 | — | — | — | |
| Johnson & Johnson | 0.91 | 0.94 | — | — | — | |
| Merck & Co. Inc. | 0.58 | 0.78 | — | — | — | |
| Pfizer Inc. | 0.78 | 0.50 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.86 | 2.81 | — | — | — | |
| Thermo Fisher Scientific Inc. | 1.63 | 1.19 | — | — | — | |
| Zoetis Inc. | 2.13 | 1.67 | — | — | — | |
| Quick Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.96 | 1.27 | — | — | — | |
| Quick Ratio, Industry | ||||||
| Health Care | 0.90 | 1.00 | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 3,959 ÷ 1,244 = 3.18
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Illumina Inc. quick ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |
Cash Ratio
Illumina Inc., cash ratio calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and cash equivalents | 1,810) | 2,042) | 1,144) | 1,225) | 735) | |
| Short-term investments | 1,662) | 1,372) | 2,368) | 920) | 824) | |
| Total cash assets | 3,472) | 3,414) | 3,512) | 2,145) | 1,559) | |
| Current liabilities | 1,244) | 665) | 1,804) | 746) | 705) | |
| Liquidity Ratio | ||||||
| Cash ratio1 | 2.79 | 5.13 | 1.95 | 2.88 | 2.21 | |
| Benchmarks | ||||||
| Cash Ratio, Competitors2 | ||||||
| AbbVie Inc. | 0.30 | 2.56 | — | — | — | |
| Amgen Inc. | 0.91 | 0.69 | — | — | — | |
| Bristol-Myers Squibb Co. | 0.83 | 0.84 | — | — | — | |
| Danaher Corp. | 0.82 | 4.04 | — | — | — | |
| Eli Lilly & Co. | 0.29 | 0.21 | — | — | — | |
| Gilead Sciences Inc. | 0.65 | 2.50 | — | — | — | |
| Johnson & Johnson | 0.59 | 0.54 | — | — | — | |
| Merck & Co. Inc. | 0.30 | 0.47 | — | — | — | |
| Pfizer Inc. | 0.47 | 0.26 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 1.33 | 1.53 | — | — | — | |
| Thermo Fisher Scientific Inc. | 1.00 | 0.39 | — | — | — | |
| Zoetis Inc. | 1.66 | 1.07 | — | — | — | |
| Cash Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.57 | 0.88 | — | — | — | |
| Cash Ratio, Industry | ||||||
| Health Care | 0.53 | 0.64 | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 3,472 ÷ 1,244 = 2.79
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Illumina Inc. cash ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |